Citadel Advisors’s SALIX PHARMACEUTICALS LTD DEL SLXP Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2015
Q2
Sell
-14,386
Closed -$2.49M 9484
2015
Q1
$2.49M Sell
14,386
-15,756
-52% -$2.31M ﹤0.01% 2799
2014
Q4
$3.46M Sell
30,142
-957,924
-97% -$116M ﹤0.01% 2335
2014
Q3
$154M Sell
988,066
-99,793
-9% -$14.5M 0.16% 102
2014
Q2
$134M Buy
1,087,859
+1,078,753
+11,847% +$119M 0.15% 107
2014
Q1
$943K Sell
9,106
-19,912
-69% -$2.04M ﹤0.01% 3502
2013
Q4
$2.61M Buy
29,018
+27,570
+1,904% +$2.2M ﹤0.01% 2281
2013
Q3
$96K Sell
1,448
-11,890
-89% -$819K ﹤0.01% 5378
2013
Q2
$882K Buy
+13,338
New +$763K ﹤0.01% 3305

Other funds holding SLXP

Citadel Advisors's SLXP Position: Q2 2015 in Review

Citadel Advisors sold out of SALIX PHARMACEUTICALS LTD DEL (SLXP) in Q2 2015, closing a stake of 14,386 shares — an estimated $2.49M sold.

Citadel Advisors first reported a position in SLXP in Q2 2013 and held it in 8 quarters. The position peaked at $154M in Q3 2014. 1 fund tracked by Wall St. Rank holds SLXP as of Q2 2015.

  • Citadel Advisors reported no remaining SALIX PHARMACEUTICALS LTD DEL position as of Q2 2015 after selling out during the quarter.
  • Citadel Advisors sold 14,386 SALIX PHARMACEUTICALS LTD DEL shares in Q2 2015, an estimated $2.49M.
  • Citadel Advisors first reported a position in SALIX PHARMACEUTICALS LTD DEL in Q2 2013 and held it in 8 quarters.
  • Citadel Advisors's SALIX PHARMACEUTICALS LTD DEL position peaked at $154M in Q3 2014.
  • 1 fund tracked by Wall St. Rank held SALIX PHARMACEUTICALS LTD DEL as of Q2 2015.

Based on Citadel Advisors's 13F filing for Q2 2015, filed 14 Aug 2015.